Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Certifies Asuragen and DeCode as BeadChip Service Providers

This article has been updated from a previous version, which incorrectly identified Asuragen as an ABI subsidiary. The details of ABI's acquisition of Ambion have also been corrected. 
 
NEW YORK (GenomeWeb News) — Illumina today said it has certified Asuragen as a gene expression profiling services provider for its Human-6 Expression BeadChip.
 
Illumina has also certified DeCode Genetics to use its Infinium BeadChip genotyping platform.
 
Asuragen, which specializes in RNA, microRNA, and gene-expression and array products and services, will use the Human-6 BeadChip for profiling services to support clinical research studies, pharmacogenomics, and biomarker discovery.
 
The company is a spin-off of Ambion's diagnostics and services division that was created in 2006 when ABI purchased Ambion’s research products division for $273 million in cash. 
 
For Decode, to become a certified service provider for Illumina’s Infinium tool, the company passed a two-phase process that included data generation and data certification, and underwent on-site audits of processes and facilities.
 
DeCode will use the BeadChip platform in conjunction with its Disease Miner software and other disease-related IP to develop DNA-based diagnostics and to offer expanded contract genotyping services to its customers.
   
DeCode’s genotyping facility is located in its headquarters in Reykjavik, Iceland.
 
DeCode and Illumina last May signed an agreement to develop and market molecular diagnostics for type II diabetes, breast cancer and heart attack.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.